WO2016112552A1 - 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 - Google Patents

牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 Download PDF

Info

Publication number
WO2016112552A1
WO2016112552A1 PCT/CN2015/070953 CN2015070953W WO2016112552A1 WO 2016112552 A1 WO2016112552 A1 WO 2016112552A1 CN 2015070953 W CN2015070953 W CN 2015070953W WO 2016112552 A1 WO2016112552 A1 WO 2016112552A1
Authority
WO
WIPO (PCT)
Prior art keywords
taurine
treatment
porcine
rotavirus
preventing
Prior art date
Application number
PCT/CN2015/070953
Other languages
English (en)
French (fr)
Inventor
王永东
操基元
祝诗发
程稳
黄志鹏
Original Assignee
广州自远生物科技有限公司
广州远图生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020177019392A priority Critical patent/KR101969007B1/ko
Priority to PL15877470T priority patent/PL3246024T3/pl
Priority to US15/543,311 priority patent/US10314799B2/en
Priority to JP2017536875A priority patent/JP6444515B2/ja
Application filed by 广州自远生物科技有限公司, 广州远图生物科技有限公司 filed Critical 广州自远生物科技有限公司
Priority to EP15877470.3A priority patent/EP3246024B1/en
Priority to UAA201707429A priority patent/UA120066C2/uk
Priority to MX2017009343A priority patent/MX2017009343A/es
Priority to DK15877470T priority patent/DK3246024T3/da
Priority to RU2017125426A priority patent/RU2678105C2/ru
Priority to ES15877470T priority patent/ES2758674T3/es
Priority to BR112017015340-8A priority patent/BR112017015340B1/pt
Priority to PCT/CN2015/070953 priority patent/WO2016112552A1/zh
Priority to CA2974024A priority patent/CA2974024C/en
Publication of WO2016112552A1 publication Critical patent/WO2016112552A1/zh
Priority to PH12017550047A priority patent/PH12017550047A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention relates to the field of disease prevention and treatment technologies, and in particular to a novel use of a known substance, and more particularly to the prevention and/or treatment of a disease caused by a coronavirus and/or a rotavirus. application.
  • Coronavirus and rotavirus can cause various diseases in livestock, and porcine viral diarrhea caused by porcine transmissible gastroenteritis virus, porcine epidemic diarrhea virus and/or porcine rotavirus has become a hazard to pigs. One of the most serious diseases.
  • the loss is inevitable; the second is that the effect of returning feed is not exact, and it usually recurs after 2 to 3 months; the third is that return feeding may bring biosafety risks, which means that the risk of other diseases may be brought to the herd. It is not worth the candle.
  • a certain dose of disinfectant such as povidone iodine is administered to the affected piglets to treat epidemic diarrhea, which has a certain effect of improving the survival rate of about 5 to 10%, but the survival of the suckling piglets has a poor prognosis. Health Long sluggish.
  • Clinically, supportive therapy is generally used to help the sick pigs to withstand, and the dehydration of sick pigs can be alleviated and corrected by drinking water containing oral rehydration salts (ORS) or intraperitoneal supplements of glucose electrolyte isotope.
  • ORS oral rehydration salts
  • Pigs, nursery pigs and adult pigs have a certain effect, but have little effect on low-aged suckling piglets in the delivery room.
  • U.S. Patent Application No. US 2014/0287065 A1 is directed to the oral administration of water containing electrolytes such as sodium hypochlorite or sodium hydroxide to pigs to reduce the incidence of dehydration of PEDV-infected large pigs, but does not provide data on the efficacy of low-aged suckling piglets in the delivery room.
  • electrolytes such as sodium hypochlorite or sodium hydroxide
  • Taurine also known as ⁇ -aminoethanesulfonic acid
  • Taurine was first isolated from the bezoar, hence the name. Pure product is colorless or white oblique crystal, odorless, taurine chemically stable, is a sulfur-containing non-protein amino acid, exists in the free state in the body, does not participate in the biosynthesis of protein in the body.
  • the use of taurine disclosed in the prior art has utility as a dietary supplement and for the use of a medicament.
  • the use as a drug includes: sulfonic acid can prevent cardiovascular diseases, cardiac and anti-arrhythmia, lowering blood fat and cholesterol, lowering blood pressure, lowering blood sugar, strengthening liver and gallbladder, as well as antipyretic, analgesic and anti-inflammatory effects.
  • Taurine is also often used as a pharmaceutical excipient in the drug group to enhance the efficacy of the main drug, improve the patient's taurine deficiency, and enhance cell protection.
  • Chinese Patent 201010505721.X discloses the effect of taurine on enhancing the main drug, andrographis extract, and the extract of Hedyotis diffusa;
  • Chinese patent application 201310072382.4 discloses synergistic action of taurine and main drug interferon against vesicular stomatitis virus and anti-mouse Encephalomyocarditis virus activity and cytoprotection.
  • taurine and compound anthocyanins can be combined to treat blue ear disease; jaundice and taurine can reduce the mortality of BALB/c mice with myocarditis caused by Coxsackie B3 virus infection.
  • the prior art does not report on the prevention and/or treatment of diseases caused by coronavirus by taurine, especially the treatment and prevention of porcine viral diarrhea by taurine.
  • the present invention provides a new medical use of taurine in order to overcome the above-mentioned deficiencies of the prior art.
  • the present invention has found that taurine can prevent and/or treat a series of diseases caused by coronaviruses such as porcine epidemic diarrhea, porcine transmissible gastroenteritis and rotavirus-induced rotavirus diarrhea. . Since both the porcine epidemic diarrhea virus and the porcine transmissible gastroenteritis virus belong to the coronavirus, the present invention claims the use of taurine in the prevention and/or treatment of diseases caused by coronavirus.
  • the present invention claims the use of taurine in the prevention and/or treatment of swine viral diarrhea.
  • Porcine viral diarrhea mainly includes porcine transmissible gastroenteritis (TGE), porcine epidemic diarrhea (PED), porcine rotavirus (PoRV), and other viruses such as enterovirus infection, porcine adenovirus infection, astrovirus, cup Swine, norovirus, parvovirus, pseudorabies virus, swine fever virus can also cause diarrhea in pigs.
  • TGE porcine transmissible gastroenteritis
  • PED porcine epidemic diarrhea
  • PoRV porcine rotavirus
  • enterovirus infection porcine adenovirus infection
  • astrovirus astrovirus
  • cup Swine norovirus
  • parvovirus parvovirus
  • pseudorabies virus pseudorabies virus
  • swine fever virus can also cause diarrhea in pigs.
  • the present invention finds that taurine is more effective in preventing and treating porcine epidemic diarrhea than porcine transmissible gastroenteritis.
  • the effect of coronavirus diarrhea is remarkable, and therefore, preferably, the present invention protects the use of taurine in the prevention and/or treatment of porcine epidemic diarrhea.
  • the invention protects the use of taurine in the prevention and/or treatment of porcine infectious gastroenteritis.
  • Rotavirus gastroenteritis is a common disease in humans and animals. It is caused by the reovirus family Rotavirus rotavirus. Although the mortality rate is not high, it is good for people, especially infants. The impact is great, and it will have a great impact on the health and production performance of pigs. Accordingly, the present invention protects the use of taurine in the prevention and/or treatment of diseases caused by rotavirus. More preferably, the invention protects the use of taurine in the prevention and/or treatment of rotavirus gastroenteritis.
  • a medicament for preventing and/or treating a disease caused by a coronavirus comprising an effective amount of taurine.
  • a medicament for preventing and/or treating porcine viral diarrhea comprising an effective amount of taurine.
  • a medicament for preventing and/or treating porcine epidemic diarrhea comprising an effective amount of taurine.
  • the present invention has the following beneficial effects:
  • taurine can prevent and/or treat a series of diseases caused by coronavirus and/or rotavirus, such as porcine epidemic diarrhea, porcine transmissible gastroenteritis and rotavirus diarrhea. .
  • the present invention also provides a new and effective way for effectively preventing and treating a series of diseases caused by coronavirus and/or rotavirus.
  • the treatment effect of taurine is the most significant. With this highly effective therapeutic drug, the breeding cost and risk can be greatly reduced for the pig industry.
  • Drug use time 3 to 30 days before delivery to 15 days after delivery, considering the cost of use, preferably 5 to 20 days before delivery to 10 days after delivery, more preferably 7 to 14 days before delivery to 5 days after delivery, the effect is obvious Time-effect relationship.
  • the length of prenatal use directly determines the incidence of postpartum newborn piglets.
  • Dosage for drug use 5 to 500 g of taurine per day for each sow, given in single or divided doses. The effect is obvious The quantity-effect relationship.
  • the treatment of neonatal piglets with taurice epidemic diarrhea is achieved by administering oral taurine solution to the affected suckling piglets, and the lactating sows are also given taurine, that is, the maternal treatment.
  • Drug use time the day of the suckling piglet on the day of onset / mixed drink, for 3 to 10 days.
  • Lactating sows Lactating sows are taken orally for 5 to 10 days.
  • Dosage for drug use on the day of the onset of suckling piglets, and/or mixed drink, administrate: 2% taurine solution, 1 ⁇ 5mL / time, 2 ⁇ 6 times / day.
  • Mixed drink 1 ⁇ 20g / L, for free drinking.
  • each sow is given 5 to 500 g of taurine per day, given in single or divided doses.
  • the method of administration can be by giving or mixing in drinking water.
  • Drug use time It is a prophylactic administration during the epidemic period, or when the temperature is low and the change is large in autumn, winter and spring, that is, the season of high incidence of porcine epidemic diarrhea. Generally, it can be administered for a long time. Considering the cost of use, it is preferably given for 3 to 30 days. More preferably, it is administered for 7 to 14 days, and the effect is in a significant time-effect relationship.
  • Dosage for drug use Add 0.005 ⁇ 2% taurine to the pig's daily drinking water for pigs to drink freely; or add 0.01-5% taurine to the feed, which is equivalent to 50 ⁇ per kg of body weight per day. 10000 mg, given in single or divided doses. The effect is a significant amount-effect relationship.
  • Treatment of weaned piglets, nursery pigs, and finishing pigs with taurine epidemic diarrhea is achieved by administering oral taurine to the herd, which can be administered by drinking water or by feeding.
  • Drug use time from the day of onset of the disease, taking into account the cost of use, preferably given 3 to 30 days, more preferably 7 to 14 days, the effect is a significant time-effect relationship.
  • Dosage for drug use add 0.1 ⁇ 2% taurine to the pig's daily drinking water for pigs to drink freely; or add 0.2-5% taurine to the feed, which is equivalent to 100 ⁇ per kg of body weight per day. 10000 mg, given in single or divided doses. The effect is a significant amount-effect relationship.
  • control group conventional supportive therapy (rehydration + antibiotic treatment + atropine sulfate)
  • experimental group taurine treatment (taurour)
  • the amount of acid used is 300 mg per kilogram of body weight per day.
  • the treatment results of the two groups are shown in Table 4. It can be seen from Table 4 that the survival rate of the experimental group is higher than that of the control group (P ⁇ 0.05).
  • Example 5 the therapeutic effect of taurine on newborn piglets, weaned piglets, nursery pigs, fattening pigs with infectious gastroenteritis, rotavirus diarrhea, pseudorabies virus diarrhea was determined. table 5.
  • the amount of taurine in the newborn piglets was the same as in Example 2; the amount of taurine in the weaned piglets, nursery pigs, and finishing pigs was the same as in Example 4.
  • taurine can treat porcine transmissible gastroenteritis and rotavirus diarrhea, but the therapeutic effect is not effective in treating porcine epidemic diarrhea, but taurine has no therapeutic effect on porcine pseudorabies viral diarrhea.
  • the pseudorabies virus belongs to the herpesvirus family (Herpesviridae), which is a highly resistant virus in the herpesvirus family. Even after 32 days of treatment with 0.5% carbolic acid, it still has an infection. On the other hand, it may also be related to the type of virus. Porcine pseudorabies virus belongs to DNA virus, while porcine epidemic diarrhea virus, porcine transmissible gastroenteritis virus and rotavirus belong to RNA virus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了牛磺酸在预防和/或治疗冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用，例如猪流行性腹泻、猪传染性胃肠炎和轮状病毒腹泻等。

Description

牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 技术领域
本发明涉及疾病预防和治疗技术领域，具体涉及一种已知物质的新用途，更具体地涉及牛磺酸在预防和/或治疗冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用。
背景技术
冠状病毒属和轮状病毒属病毒可以引发牲畜的各种疾病，其中由猪传染性胃肠炎病毒、猪流行性腹泻病毒和/或猪轮状病毒等引起的猪病毒性腹泻已成为危害猪生产最严重的疾病之一。
迄今为止，对于猪病毒性腹泻尚无有效的预防或治疗的方法，原因如下：
一方面，有效、可靠的疫苗尚未研发成功。近年来，分离得到猪流行性腹泻病毒毒株与CV777的基因同源性只有86～98％不等，预示疫苗研发的难度非常大，事实上，中国目前批准的商品化PED疫苗，或PED/TGE二联苗，以及正在研发的PED/TGE/PoRV三联苗，对流行性腹泻的保护率均不理想。美国于2014年批准上市的PED疫苗也面临同样的问题。目前，世界各地尤其是美国，大量地采用返饲技术来处理本病，同样是无奈之举，一是返饲需要病料，换言之只有发病后才能获得返饲需要的材料，而本病一旦发生损失在所难免；二是返饲的效果不确切，一般2～3个月后又会复发；三是返饲可能带来生物安全风险，也就是说可能给猪群带来其他疾病爆发的风险，得不偿失。
另一方面，现有的预防或治疗的药物效果并不确切，如干扰素、卵黄抗体、胸腺肽等对猪病毒性腹泻效果均不理想。Kim等的研究表明抗病毒药物利巴韦林能抑制PEDV的复制(Virus Research(2013),171(1),44-53)，但是世界各国的法规均禁止人用抗病毒药用于食品动物，在预防和治疗猪流行性腹泻时，不能采用利巴韦林、金刚烷胺等抗病毒药物。Lee等研究发现银杏外种皮提取的多糖在体外对PEDV有抑制作用，活性优于利巴韦林，是一种潜在的抗PEDV物质(Virus Research(2015),195,148-152)，但也仅仅限于体外实验，体内效果如何还需大量的实验。中国专利2013100930843、201310147391.5等则是采用中药材组合、直接粉碎后治疗和预防猪流行性腹泻，一般见效时间长，效果有限，尤其是对产房新生仔猪几乎没有效果。
再一方面，临床上也有采用给发病仔猪口服一定剂量的聚维酮碘等消毒剂来治疗流行性腹泻，有一定的效果能够提高约5～10％的存活率，但存活的哺乳仔猪预后不良，生 长迟缓。临床上一般还采用支持疗法以帮助病猪耐过，通过给病猪饮用含口服补液盐(ORS)的水或腹腔补充葡萄糖电解质等渗液的方法来缓解、纠正病猪脱水，此法对断奶猪、保育猪和成年猪有一定的效果，但对产房低日龄哺乳仔猪效果甚微。美国专利申请US2014/0287065A1采取的是给猪口服含有次氯酸钠、氢氧化钠等电解质的水降低PEDV感染的中大猪的脱水发生率，但没有提供对产房低日龄哺乳仔猪效果数据。
牛磺酸(taurine)又称β-氨基乙磺酸，最早由牛黄中分离出来，故得名。纯品为无色或白色斜状晶体，无臭，牛磺酸化学性质稳定，是一种含硫的非蛋白氨基酸，在体内以游离状态存在，不参与体内蛋白的生物合成。现有技术公开的牛磺酸的用途有作为膳食补充剂的用途和药物的用途。作为药物的用途包括：磺酸可以防治心血管病，强心和抗心率失常、降血脂和胆固醇、降血压、降血糖、强肝利胆，还有解热、镇痛和抗炎等作用。牛磺酸还常常作为药物辅料，添加于药物组方中，用于增强主药疗效、改善患者牛磺酸缺乏、增强细胞保护的目的。中国专利201010505721.X公开了牛磺酸增强主药穿心莲酯、白花蛇舌草提取物的效果；中国专利申请201310072382.4公开了牛磺酸与主药干扰素协同作用抗水疱性口炎病毒和抗鼠脑心肌炎病毒活性和细胞保护作用。另外，前人报道牛磺酸和复方花青素、阿司匹林混合可以治疗猪蓝耳病；黄芪和牛磺酸可以减少柯萨奇B3病毒感染所致心肌炎BALB/c小鼠的死亡率。但是，现有技术并没有关于牛磺酸预防和/或治疗由冠状病毒属病毒引发疾病的报道，尤其是牛磺酸对猪病毒性腹泻的治疗和预防的报道。
发明内容
本发明为了克服现有技术的上述不足，提供牛磺酸的新的医药用途。
为了实现上述目的，本发明是通过以下方案予以实现的。
本发明通过研究发现牛磺酸可以预防和/或治疗由冠状病毒属病毒引发的一系列疾病如猪流行性腹泻、猪传染性胃肠炎及轮状病毒属病毒引发的轮状病毒腹泻等疾病。由于猪流行性腹泻病毒和猪传染性胃肠炎病毒都属于冠状病毒属病毒，因此本发明要求保护，牛磺酸在预防和/或治疗冠状病毒属病毒引发的疾病中的应用。
同时，本发明要求保护牛磺酸在预防和/或治疗猪病毒性腹泻中的应用。
猪病毒性腹泻主要有猪传染性胃肠炎(TGE)、猪流行性腹泻(PED)、猪轮状病毒(PoRV)，同时其他病毒如肠病毒感染、猪腺病毒感染、星状病毒、杯状病毒、诺瓦克病毒、细小病毒、伪狂犬病毒、猪瘟病毒也可以引起猪只的腹泻。
因为，本发明发现牛磺酸对猪流行性腹泻的预防和治疗作用明显比猪传染性胃肠炎 和冠状病毒性腹泻的效果显著，因此，优选地，本发明保护牛磺酸在预防和/或治疗猪流行性腹泻中的应用。
优选地，本发明保护牛磺酸在预防和/或治疗猪传染性胃肠炎中的应用。
轮状病毒性胃肠炎，是一种人畜共患的常见病，是由呼肠孤病毒科轮状病毒属轮状病毒引起的，虽然死亡率不高，但对人尤其是婴幼儿的健康影响很大，对猪的健康及生产性能也会造成很大影响。因此，本发明保护牛磺酸在预防和/或治疗轮状病毒属病毒引发的疾病中的应用。更优选地，本发明保护牛磺酸在预防和/或治疗轮状病毒性胃肠炎中的应用。
一种预防和/或治疗冠状病毒属病毒引发的疾病的药物，包括有效量的牛磺酸。
一种预防和/或治疗猪病毒性腹泻的药物，包括有效量的牛磺酸。
一种预防和/或治疗猪流行性腹泻的药物，包括有效量的牛磺酸。
与现有技术相比，本发明具有以下有益效果：
本发明首次研究发现牛磺酸可以预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的一系列疾病，如猪流行性腹泻、猪传染性胃肠炎及轮状病毒腹泻等。这为牛磺酸的医药用途开发了新的应用领域，同时，本发明也为有效预防和治疗冠状病毒属和/或轮状病毒属病毒引发的一系列疾病提供了新的有效途径。尤其是对猪流行性腹泻，牛磺酸的治疗效果最显著，有了这种高效的治疗药物，就可以为养猪产业大大降低养殖成本和风险。
具体实施方式
下面通过具体实施例对本发明进一步具体描述。下述所使用的实验方法若无特殊说明，均为本技术领域现有常规的方法，所使用的配料或材料，如无特殊说明，均为通过商业途径可得到的配料或材料。以下所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以作出若干改进，这些改进也应视为本发明的保护范围。
实施例1牛磺酸在预防新生仔猪流行性腹泻中的应用
用牛磺酸预防新生仔猪流行性腹泻是通过给予待产母猪口服牛磺酸实现的。
药物使用时间：是产前喂3～30天至产后15天，考虑到使用成本，优选产前5～20天至产后10天，更优选产前7～14天至产后5天，效果呈明显的时-效关系。产前使用时间长短直接决定产后新生仔猪的发病率高低。
药物使用剂量：每头母猪每天给予5～500g的牛磺酸，单次或分次给予。效果呈明显 的量-效关系。
具体操作：选取待产母猪，用RT-PCR测定其粪便，确认其体内带有PEDV，60头带毒的待产母猪，随机分成2组。对照组：常规饲养，实验组：常规饲养+牛磺酸50g/头/天。两组的预防结果见表1。由表1可以看出使用牛磺酸的实验组发病率及死亡率均较对照组有明显下降(P<0.01)。
表1
组别 牛磺酸用量 新生仔猪发病率(％) 新生仔猪死亡率(％)
对照组 0 100％ 96.6％
实验组 50g/头/天 85％ 75.1％
实施例2牛磺酸在治疗新生仔猪流行性腹泻中的应用
用牛磺酸治疗新生仔猪流行性腹泻是通过给予已发病哺乳仔猪口服牛磺酸溶液，并且其哺乳母猪也要给予牛磺酸，即母仔同治实现的。
药物使用时间：哺乳仔猪发病当天灌服/混饮，连用3～10天。哺乳母猪：哺乳母猪口服，连用5～10天。
药物使用剂量：哺乳仔猪发病当天灌服和/或混饮，灌服：2％牛磺酸溶液，1～5mL/次，2～6次/天。混饮：1～20g/L，供其自由饮用。哺乳母猪，每头母猪每天给予5～500g的牛磺酸，单次或分次给予。
具体操作：选取发病的新生哺乳仔猪及其母猪40窝。随机等量分成2组，对照组：常规支持性疗法(补液+抗生素治疗+硫酸阿托品)，实验组：牛磺酸治疗。两组的治疗结果见表2。由表2可以看出实验组仔猪10日龄存活率、断奶存活率均较对照组有显著提高(P<0.05)，且仔猪预后良好。
表2
Figure PCTCN2015070953-appb-000001
实施例3牛磺酸在预防断奶仔猪、保育猪、肥育猪流行性腹泻中的应用
用牛磺酸预防断奶仔猪、保育猪、肥育猪流行性腹泻是通过给予猪群口服牛磺酸实 现的，服用方式可以通过在饮水中给予或混饲的方式。
药物使用时间：是在疾病流行期间，或者是秋冬春气温低、变化大时即猪流行性腹泻高发季节作预防性给药，一般可长期给予，考虑到使用成本，优选给予3～30天，更优选给予7～14天，效果呈明显的时-效关系。
药物使用剂量：在猪日常饮水中添加0.005～2％的牛磺酸，供猪只自由饮用；或者在饲料中加入0.01～5％的牛磺酸，相当于每公斤体重每日摄入50～10000mg，单次或分次给予。效果呈明显的量-效关系。
具体操作：选取健康的断奶仔猪、保育猪、肥育猪各120头。随机等量分成2组，对照组：常规饲养，实验组：常规饲养+牛磺酸(牛磺酸用量为每公斤体重每日摄入200mg)。两组的预防结果见表3。由表3可以看出实验组的发病率较对照组降低(P<0.05)，实验组的存活率较对照组更高(P<0.05)
表3
Figure PCTCN2015070953-appb-000002
实施例4牛磺酸在治疗断奶仔猪、保育猪、肥育猪流行性腹泻中的应用
用牛磺酸治疗断奶仔猪、保育猪、肥育猪流行性腹泻是通过给予猪群口服牛磺酸实现的，服用方式可以通过在饮水中给予或混饲的方式。
药物使用时间：从发病当日开始给予，考虑到使用成本，优选给予3～30天，更优选给予7～14天，效果呈明显的时-效关系。
药物使用剂量：在猪日常饮水中添加0.1～2％的牛磺酸，供猪只自由饮用；或者在饲料中加入0.2～5％的牛磺酸，相当于每公斤体重每日摄入100～10000mg，单次或分次给予。效果呈明显的量-效关系。
具体操作：选取发病的断奶仔猪、保育猪、肥育猪各60头。随机等量分成2组，对照组：常规支持性疗法(补液+抗生素治疗+硫酸阿托品)，实验组：牛磺酸治疗(牛磺 酸用量为每公斤体重每日摄入300mg)。两组的治疗结果见表4。由表4可以看出实验组较对照组的存活率更高(P<0.05)
表4
Figure PCTCN2015070953-appb-000003
实施例5
按照实施例2和实施例4所述的方法，测定牛磺酸对新生仔猪、断奶仔猪、保育猪、肥育猪传染性胃肠炎、轮状病毒性腹泻、伪狂犬病毒性腹泻的治疗效果，见表5。新生仔猪的牛磺酸用量同实施例2；断奶仔猪、保育猪、肥育猪的牛磺酸用量同实施例4。由表5可知，牛磺酸可以治疗猪传染性胃肠炎、轮状病毒性腹泻，只是治疗效果没有治疗猪流行性腹泻的效果好，但是牛磺酸对于猪伪狂犬病毒性腹泻却没有治疗效果，原因可能是：一方面，猪伪狂犬病毒属于疱疹病毒科(Herpesviridae)猪疱疹病毒属病毒，该病毒是疱疹病毒科中抵抗力较强的病毒，甚至经0.5％石炭酸处理32天后仍具有感染性；另一方面，也可能与病毒的种类有关，猪伪狂犬病毒属于DNA病毒，而猪流行性腹泻病毒、猪传染性胃肠炎病毒和轮状病毒均属于RNA病毒。
表5
Figure PCTCN2015070953-appb-000004
Figure PCTCN2015070953-appb-000005

Claims (10)

  1. 牛磺酸在预防和/或治疗冠状病毒属病毒引发的疾病中的应用。
  2. 牛磺酸在预防和/或治疗猪病毒性腹泻中的应用。
  3. 牛磺酸在预防和/或治疗猪流行性腹泻中的应用。
  4. 牛磺酸在预防和/或治疗猪传染性胃肠炎中的应用。
  5. 牛磺酸在预防和/或治疗轮状病毒属病毒引发的疾病中的应用。
  6. 一种预防和/或治疗冠状病毒属病毒引发的疾病的药物，其特征在于，包括有效量的牛磺酸。
  7. 一种预防和/或治疗轮状病毒属病毒引发的疾病的药物，其特征在于，包括有效量的牛磺酸。
  8. 一种预防和/或治疗猪病毒性腹泻的药物，其特征在于，包括有效量的牛磺酸。
  9. 一种预防和/或治疗猪流行性腹泻的药物，其特征在于，包括有效量的牛磺酸。
  10. 根据权利要求1至5任一项应用，其特征在于，牛磺酸的有效用量为10～20000mg/公斤体重。
PCT/CN2015/070953 2015-01-17 2015-01-17 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用 WO2016112552A1 (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
UAA201707429A UA120066C2 (uk) 2015-01-17 2015-01-17 Застосування таурину для профілактики і/або лікування захворювань, викликаних вірусами роду коронавірусів і/або роду ротавірусів
US15/543,311 US10314799B2 (en) 2015-01-17 2015-01-17 Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
JP2017536875A JP6444515B2 (ja) 2015-01-17 2015-01-17 タウリンのコロナウイルス属及び／又はロタウイルス属のウィルスにより引き起こされる疾患の予防及び／又は治療における応用
DK15877470T DK3246024T3 (da) 2015-01-17 2015-01-17 Anvendelse af taurin i forebyggelse og/eller behandling af sygdomme induceret af vira af slægten coronavirus og/eller slægten rotavirus
EP15877470.3A EP3246024B1 (en) 2015-01-17 2015-01-17 Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
PL15877470T PL3246024T3 (pl) 2015-01-17 2015-01-17 Zastosowanie tauryny w zapobieganiu i/lub leczeniu chorób wywoływanych przez wirusy z rodzaju koronawirusa i/lub rodzaju rotawirusa
MX2017009343A MX2017009343A (es) 2015-01-17 2015-01-17 Uso de taurina en la prevención y/o el tratamiento de enfermedades inducidas por virus del género coronavirus y/o del género rotavirus.
KR1020177019392A KR101969007B1 (ko) 2015-01-17 2015-01-17 코로나바이러스속 및/또는 로타바이러스속 바이러스로 인한 질병의 예방 및/또는치료에 있어서의 타우린의 응용
RU2017125426A RU2678105C2 (ru) 2015-01-17 2015-01-17 Применение таурина для профилактики и/или лечения заболеваний, вызванных вирусами рода коронавирусов и/или рода ротавирусов
ES15877470T ES2758674T3 (es) 2015-01-17 2015-01-17 Uso de taurina en la prevención y/o tratamiento de enfermedades inducidas por los virus del género coronavirus y/o del género rotavirus
BR112017015340-8A BR112017015340B1 (pt) 2015-01-17 2015-01-17 Uso de taurina na prevenção e/ou tratamento de doenças induzidas por vírus do gênero coronavírus e/ou gênero rotavírus
PCT/CN2015/070953 WO2016112552A1 (zh) 2015-01-17 2015-01-17 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用
CA2974024A CA2974024C (en) 2015-01-17 2015-01-17 Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
PH12017550047A PH12017550047A1 (en) 2015-01-17 2017-07-17 Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/070953 WO2016112552A1 (zh) 2015-01-17 2015-01-17 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用

Publications (1)

Publication Number Publication Date
WO2016112552A1 true WO2016112552A1 (zh) 2016-07-21

Family

ID=56405151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/070953 WO2016112552A1 (zh) 2015-01-17 2015-01-17 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用

Country Status (14)

Country Link
US (1) US10314799B2 (zh)
EP (1) EP3246024B1 (zh)
JP (1) JP6444515B2 (zh)
KR (1) KR101969007B1 (zh)
BR (1) BR112017015340B1 (zh)
CA (1) CA2974024C (zh)
DK (1) DK3246024T3 (zh)
ES (1) ES2758674T3 (zh)
MX (1) MX2017009343A (zh)
PH (1) PH12017550047A1 (zh)
PL (1) PL3246024T3 (zh)
RU (1) RU2678105C2 (zh)
UA (1) UA120066C2 (zh)
WO (1) WO2016112552A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109223716B (zh) * 2018-09-03 2020-10-30 北京普飞特生物科技有限公司 一种抗猪流行性腹泻、猪瘟、伪狂犬和传染性胃肠炎的四联卵黄抗体可溶性粉及其制备方法
IT202000012325A1 (it) * 2020-05-26 2021-11-26 Blueprint Pharma Srl Metotrexato per l’uso nel trattamento di infezioni virali in animali da allevamento
WO2021240375A1 (en) * 2020-05-26 2021-12-02 Blueprint Pharma S.R.L. Methotrexate for use in the pharmaceutical or veterinary prevention and/or treatment of viral infections
CN115350170B (zh) * 2022-08-29 2023-08-29 浙江省农业科学院 牛磺酸在制备提高中华鳖抗病毒性腮腺炎病能力的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101869151A (zh) * 2010-07-08 2010-10-27 湖南澳优食品与营养研究院 一种含乳凝集素的婴幼儿奶粉及其制备方法
CN103417570A (zh) * 2013-08-30 2013-12-04 天津生机集团股份有限公司 用于治疗猪细菌腹泻的组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000044473A (ja) * 1998-07-27 2000-02-15 Mitsui Norin Co Ltd 家畜のウイルス感染予防剤
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
KR100419191B1 (ko) * 2003-06-23 2004-02-19 주식회사 엔바이오테크놀러지 독감 인플루엔자 바이러스 및 전염성 위장염 코로나바이러스 억제 활성을 갖는 효모변이주 아이에스2 유래수용성 글루칸 올리고머를 함유하는 조성물
US7879030B2 (en) * 2005-07-27 2011-02-01 St. Jude Medical, Atrial Fibrillation Division, Inc. Multipolar, virtual-electrode catheter with at least one surface electrode and method for ablation
KR100720151B1 (ko) * 2005-12-13 2007-05-18 한국생명공학연구원 항바이러스 활성을 갖는 플라보노이드 화합물
CN101966245B (zh) * 2010-10-13 2011-11-30 郑州后羿制药有限公司 一种治疗畜禽病毒性疾病的复方注射液及其制备方法
CN103006811B (zh) * 2012-12-29 2014-02-19 潍坊富邦药业有限公司 一种撒在初生仔猪的体表预防疾病的方剂及制备工艺
CN103341160B (zh) 2013-02-27 2015-11-11 澳蒲生物科技(上海)有限公司 一种含有干扰素的药物组合物及其应用
US9283250B2 (en) 2013-03-14 2016-03-15 Ag Odor Control, LLC Oral administration of electrolyzed water for treatment and prevention of PEDv in swine, swine herds and swine confinements
CN103127416B (zh) 2013-03-22 2014-11-26 刘荣彬 一种预防和治疗猪传染性胃肠炎和流行性腹泻的药物
CN103230574B (zh) 2013-04-25 2014-09-17 中国农业科学院兰州畜牧与兽药研究所 一种治疗猪流行性腹泻的中药组合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101869151A (zh) * 2010-07-08 2010-10-27 湖南澳优食品与营养研究院 一种含乳凝集素的婴幼儿奶粉及其制备方法
CN103417570A (zh) * 2013-08-30 2013-12-04 天津生机集团股份有限公司 用于治疗猪细菌腹泻的组合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3246024A4 *

Also Published As

Publication number Publication date
BR112017015340A2 (zh) 2018-01-09
PL3246024T3 (pl) 2020-03-31
JP6444515B2 (ja) 2018-12-26
ES2758674T3 (es) 2020-05-06
JP2018501294A (ja) 2018-01-18
PH12017550047B1 (en) 2018-02-05
US10314799B2 (en) 2019-06-11
CA2974024C (en) 2020-01-21
KR20170106962A (ko) 2017-09-22
EP3246024A1 (en) 2017-11-22
DK3246024T3 (da) 2019-12-09
RU2017125426A3 (zh) 2019-01-18
BR112017015340B1 (pt) 2022-10-11
US20170368006A1 (en) 2017-12-28
CA2974024A1 (en) 2016-07-21
PH12017550047A1 (en) 2018-02-05
UA120066C2 (uk) 2019-09-25
MX2017009343A (es) 2017-11-15
EP3246024B1 (en) 2019-09-25
KR101969007B1 (ko) 2019-04-15
RU2678105C2 (ru) 2019-01-23
EP3246024A4 (en) 2018-10-24
RU2017125426A (ru) 2019-01-18

Similar Documents

Publication Publication Date Title
DK2224918T3 (en) The use of EDTA and its salts for the prevention and treatment of bacterial intestinal diseases of pigs
WO2016112552A1 (zh) 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用
WO2016112553A1 (zh) 一种预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病的药物组合物
US10881621B2 (en) Sintered ferrous amino acid particles and use of the same against a virus
CN105832759B (zh) 一种预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病的药物组合物
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
CN108096443B (zh) 一种清除畜禽体内毒素、提升机体免疫力的药物、其制备方法及应用
US11141382B2 (en) Sintered nanoparticles and use of the same against a virus
CN109316598B (zh) 一种防治猪腹泻的中药、抗菌肽与中草药复合制剂及制备方法和应用
JP2013231073A (ja) 生物学的平衡化合物の投与による病原体の減衰
CN108635492A (zh) 一种防治鸽毛滴虫病的中药组合物及其制备方法与应用
CN101530405B (zh) 柠檬酸及复方柠檬酸在制药中的应用
CN116847854A (zh) 包含岩藻糖基乳糖作为有效成分的抗病毒组合物
CN105832714B (zh) 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用
CN101972325A (zh) 用于治疗鸡球虫病的药物组合物及其制备方法
CN107307214B (zh) 一种治疗猪腹泻的饲料添加剂
WO2006095433A1 (ja) ウシの消化器疾患治療剤
JP2001213774A (ja) ウイルス感染症予防剤
CA3154962A1 (en) Antioxidant nutritional supplement for immune system support
WO2022091023A1 (en) Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system
CN116966264A (zh) 一种具有协同缓解便秘作用的小麦肽组合物及其应用
CN116847862A (zh) 甘蔗提取物在治疗或预防微生物感染和生态失调中的用途
CN112315999A (zh) 用于预防和治疗猪流感的中药制剂及其制备方法
CN105796693A (zh) 一种防治白喉型鸡痘的药物组合物及其制备方法和应用
CN103127157A (zh) 一种治疗禽畜上呼吸道疾病的药物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15877470

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017536875

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177019392

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15543311

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2974024

Country of ref document: CA

Ref document number: 2017125426

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015877470

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12017550047

Country of ref document: PH

Ref document number: MX/A/2017/009343

Country of ref document: MX

Ref document number: A20170271

Country of ref document: BY

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017015340

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017015340

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170717